Understanding how APOBEC mutations affect breast cancer
APOBEC MUTAGENESIS IN BREAST CANCER
This study is looking at how certain genetic changes caused by APOBEC enzymes affect breast cancer, especially in patients with estrogen receptor-positive breast cancer, with the goal of finding ways to block these changes to help improve treatment and outcomes.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-10692655 on NIH RePORTER |
What this research studies
This research investigates the role of APOBEC mutations in breast cancer, particularly focusing on how these mutations contribute to the progression and treatment resistance of the disease. By analyzing the genetic changes caused by APOBEC enzymes, the research aims to develop methods to inhibit these mutations, potentially leading to improved treatment outcomes for patients with estrogen receptor-positive breast cancer. The study involves multidisciplinary projects that will work together to quantify APOBEC activity and assess the impact of its inhibition on tumor progression and patient survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with estrogen receptor-positive breast cancer, particularly those with operable disease or recurrent metastases.
Not a fit: Patients with other types of breast cancer or those who are not estrogen receptor-positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of existing therapies for breast cancer patients.
How similar studies have performed: Previous research has shown that targeting mutagenesis pathways can improve treatment outcomes in cancer, suggesting that this approach may hold promise.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Harris, Reuben S — University of Texas Hlth Science Center
- Study coordinator: Harris, Reuben S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.